Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications

被引:65
作者
Petrilla, AA
Benner, JS
Battleman, DS
Tierce, JC
Hazard, EH
机构
[1] ValueMedics Res LLC, Falls Church, VA 22046 USA
[2] Pfizer Inc, Dept Outcomes Res, New York, NY USA
[3] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
关键词
patient compliance; intervention studies; reminder systems; antihypertensive agents; antilipemic agents;
D O I
10.1111/j.1368-5031.2005.00704.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The MEDLINE database was searched from 1972 to June 2002 to identify studies of interventions designed to improve compliance with antihypertensive or lipid-lowering medications. Studies were required to employ a controlled design, follow patients for >= 6 months and measure compliance by a method other than patient self-report. The literature review yielded 62 studies describing 79 interventions. Overall, 56% of interventions were reported to improve patient compliance. When only those studies meeting minimum criteria for methodological quality were considered, 22 interventions remained and 12 were recommended, because they demonstrated a significant improvement in compliance. Recommended interventions included fixed-dose combination drugs, once-daily or once-weekly dosing schedules, unit-dose packaging, educational counselling by telephone, case management by pharmacists, treatment in pharmacist- or nurse-operated disease management clinics, mailed refill reminders, self-monitoring, dose-tailoring, rewards and various combination strategies. Personalised, patient-focused programs that involved frequent contact with health professionals or a combination of interventions were the most effective at improving compliance. Less-intensive strategies, such as prescribing products that simplify the medication regimen or sending refill reminders, achieved smaller improvements in compliance but may be cost-effective due to their low cost.
引用
收藏
页码:1441 / 1451
页数:11
相关论文
共 70 条
  • [1] DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS
    ANDRADE, SE
    WALKER, AM
    GOTTLIEB, LK
    HOLLENBERG, NK
    TESTA, MA
    SAPERIA, GM
    PLATT, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) : 1125 - 1131
  • [2] [Anonymous], 2005, HEART DIS STROKE STA
  • [3] ASCIONE FJ, 1984, DRUG INTEL CLIN PHAR, V18, P926, DOI 10.1177/106002808401801121
  • [4] Relationship between home blood pressure measurement and medication compliance and name recognition of antihypertensive drugs
    Ashida, T
    Sugiyama, T
    Okuno, S
    Ebihara, A
    Fujii, J
    [J]. HYPERTENSION RESEARCH, 2000, 23 (01) : 21 - 24
  • [5] Persistence of use of lipid-lowering medications - A cross-national study
    Avorn, J
    Monette, J
    Lacour, A
    Bohn, RL
    Monane, M
    Mogun, H
    LeLorier, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18): : 1458 - 1462
  • [6] BAIRD MG, 1984, CLIN INVEST MED, V7, P95
  • [7] PSYCHOLOGICAL GROUP TREATMENT OF ESSENTIAL-HYPERTENSION IN GENERAL-PRACTICE
    BASLER, HD
    BRINKMEIER, U
    BUSER, K
    HAEHN, KD
    MOLDERSKOBER, R
    [J]. BRITISH JOURNAL OF CLINICAL PSYCHOLOGY, 1982, 21 (NOV) : 295 - 302
  • [8] BECKER LA, 1986, J FAM PRACTICE, V22, P357
  • [9] Long-term persistence in use of statin therapy in elderly patients
    Benner, JS
    Glynn, RJ
    Mogun, H
    Neumann, PJ
    Weinstein, MC
    Avorn, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04): : 455 - 461
  • [10] BERG JS, 1993, ANN PHARMACOTHER, V27, pS1